NEOADJUVANT THERAPY
Clinical trials for NEOADJUVANT THERAPY explained in plain language.
Never miss a new study
Get alerted when new NEOADJUVANT THERAPY trials appear
Sign up with your email to follow new studies for NEOADJUVANT THERAPY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New Pre-Surgery combo aims to wipe out colon cancer cells
Disease control OngoingThis study is testing a new treatment approach for people with a common type of locally advanced colon cancer. Before having standard surgery, participants receive a combination of an immunotherapy drug (tislelizumab) and two chemotherapy drugs (oxaliplatin and capecitabine). The…
Matched conditions: NEOADJUVANT THERAPY
Phase: PHASE2 • Sponsor: First Affiliated Hospital of Guangxi Medical University • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New combo treatment aims to shrink tumors before lung cancer surgery
Disease control OngoingThis study is testing whether adding an immunotherapy drug called serplulimab to standard chemotherapy before surgery helps people with operable non-small cell lung cancer. The goal is to see if this combination treatment can better shrink tumors before removal, lower the chance …
Matched conditions: NEOADJUVANT THERAPY
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Study tests if chemo first beats surgery alone for tough kidney cancer
Disease control OngoingThis study compares two treatment approaches for a type of cancer in the upper urinary tract. One group gets chemotherapy before surgery, while the other gets surgery right away. Researchers want to see if shrinking the tumor with chemo first leads to better long-term results for…
Matched conditions: NEOADJUVANT THERAPY
Phase: PHASE2 • Sponsor: Changhai Hospital • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New combo therapy aims to shrink tumors before esophageal cancer surgery
Disease control OngoingThis study is testing whether adding an immunotherapy drug called serplulimab to standard chemotherapy before surgery is safe and effective for people with a type of esophageal cancer that can be removed by surgery. The goal is to see if this combination treatment can better shri…
Matched conditions: NEOADJUVANT THERAPY
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
Immunotherapy combo aims to boost survival in tough head & neck cancer
Disease control OngoingThis study is testing whether adding an immunotherapy drug (a PD-1 inhibitor) to standard chemotherapy before a patient's main cancer treatment can help people with advanced nasopharyngeal cancer live longer without their cancer returning. It involves 150 participants who are ran…
Matched conditions: NEOADJUVANT THERAPY
Phase: PHASE2 • Sponsor: Guangxi Medical University • Aim: Disease control
Last updated Mar 17, 2026 13:10 UTC
-
New 'Double-Action' drug tested to shrink lung tumors before surgery
Disease control OngoingThis study is testing a new drug called Ivonescimab for people with non-small cell lung cancer who need surgery. It compares this new drug, which works by blocking two different cancer pathways at once, to standard immunotherapy drugs. The main goal is to see if the new drug is b…
Matched conditions: NEOADJUVANT THERAPY
Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Mar 13, 2026 15:05 UTC